Human medicines European public assessment report (EPAR): Zilbrysq, zilucoplan, Date of authorisation: 01/12/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Mvasi, bevacizumab, Date of authorisation: 15/01/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, Respiratory syncytial virus mRNA vaccine (nucleoside modified), Date of authorisation: 22/08/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Revision: 3, Status: Authorised

Seventh European Medicines Agency - EuropaBio bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 20 January 2026, 10:00 (CET) to 20 January 2026, 12:00 (CET)

Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746) - tracked changes

Questions and answers on implementation of the medical devices and in vitro diagnostic medical devices Regulations ((EU) 2017/745 and (EU) 2017/746)

Sixth European Medicines Agency (EMA) and the Association of the European Self-Care Industry (AESGP) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 January 2026, 14:00 (CET) to 23 January 2026, 16:00 (CET)

Transfer of marketing authorisation: questions and answers

Submitting results of paediatric studies